TKMR


Friday Insights: Fitbit Inc (FIT), Tekmira Pharmaceuticals Corp (TKMR), Erickson Inc (EAC), AirMedia Group Inc (AMCN)

Fitbit Inc (NYSE:FIT) shares are up 11.19% in mid-day trading to $33.

A Roundup of Our Top Stories in Healthcare From the Week

One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …

Tekmira Pharmaceuticals: Spinning Its Next ‘Big Story’

By Sonya Colberg, TheStreetSweeper Senior Investigative Reporter Tekmira Pharmaceuticals (NASDAQ:TKMR) may not have found its next big biotech thing, after all. After a …

Maxim Maintains Buy On Tekmira Pharma As HBV Antisense Therapy Moves Into The Clinic

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $27 price …

Tekmira/Oncore Merger Represents Substantial Upside

Well, one IPO we were eagerly awaiting is no longer on this year’s docket with Tekmira’s (NASDAQ:TKMR) merger agreement with Oncore announced tonight …

Maxim Cuts Tekmira Pharmaceuticals Price Target As Ebola Development Will Likely Require Additional Time

In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Tekmira Pharmaceuticals (NASDAQ:TKMR) and reduced his …

Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates

Tekmira Pharmaceuticals (NASDAQ: TKMR) is a biopharmaceutical company based in Vancouver, Canada. Tekmira prides itself on creating drugs to combat cancers, viral infections, and …

Tekmira Pharmaceuticals Corporation: Bulls Vs. Bears

Shares of Tekmira Pharmaceuticals Corporation slipped by as much as 2% during regular trading hours today Much of Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s valuation …

Maxim Maintains Buy On Tekmira Following 3Q14 Results

Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $31 price target, which represents a potential upside …

Maxim Group Reiterates Buy On Tekmira Following An Update On Its Ebola Program

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $31 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts